Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization

[Display omitted] The derivatization of pharmaceuticals is a core activity in the discovery and development of new medicines. Late-stage functionalization via modern CH functionalization chemistry has emerged as a powerful technique with which to diversify advanced pharmaceutical intermediates. We r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2019-07, Vol.29 (14), p.1854-1858
Hauptverfasser: Liu, Kun, Kurukulasuriya, Ravi, Dykstra, Kevin, DiMichelle, Lisa, Liu, Jinchu, Vachal, Petr, Ogawa, Anthony, DeVita, Robert J., Shen, Dong-Ming, Tan, Qiang, Chen, Yili, Gauthier, Don, Verras, Andreas, Crespo, Alejandro, Zamlynny, Beata, Madwed, Jeffrey, Hoek, Maarten, Bateman, Thomas, Yang, Yun-Fang, Houk, K.N., Krska, Shane, Cernak, Tim
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] The derivatization of pharmaceuticals is a core activity in the discovery and development of new medicines. Late-stage functionalization via modern CH functionalization chemistry has emerged as a powerful technique with which to diversify advanced pharmaceutical intermediates. We report herein a case study in late-stage functionalization towards the development of a new class of indazole-based mineralocorticoid receptor antagonists (MRA). An effort to modify the electronics of the core indazole heterocycle inspired the use of modern CH borylation chemistry. New reactivity patterns were revealed and studied computationally. Ultimately, a de novo synthesis delivered a key 6-fluoroindazole compound 26, a potent MRA with excellent metabolic stability.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2019.04.024